Trump Administration Gives Compounders Temporary Access to Six Unapproved Peptides
HHS directed the FDA to temporarily refrain from enforcement against qualifying pharmacies that compound six unapproved peptides while the agency considers a formal rule change.
The Trump administration is allowing qualifying compounding pharmacies to make six unapproved peptide products while federal regulators pursue a formal rule change. The Department of Health and Human Services announced the temporary enforcement policy on Wednesday, October 28, 2026, directing the Food and Drug Administration not to take action against pharmacies that meet the policy’s conditions.
The six substances are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. They are promoted online for uses that include injury recovery, energy, skin appearance and longevity, but none has been approved by the FDA as safe and effective. The policy therefore does not amount to FDA approval, and it does not establish that the products work for the claims made about them.
What the temporary policy changes
Compounding pharmacies generally may use bulk ingredients only when federal law permits them or the FDA has placed them on an authorized list. HHS is instead using enforcement discretion while the FDA works through the rulemaking process. In practical terms, the government says it will temporarily refrain from legal action against qualifying compounders that make the six peptides even though the ingredients have not yet been added to that list.
The policy includes safeguards. According to NBC News and the Associated Press report republished by PBS NewsHour, compounders must verify the identity and purity of the substances, use ingredients from FDA-registered facilities and collect or report information about adverse events. Those conditions address product-quality risks but do not replace the clinical evidence normally required for an FDA approval decision.
FDA scientists raised safety and process objections
The Associated Press reported that most FDA scientific staff involved in the issue opposed widening access and had limited input as HHS developed the plan, citing six people familiar with confidential deliberations. The report said FDA staff warned that the approach could weaken the agency’s longstanding safeguards against unproven drugs. HHS did not immediately answer the AP’s request for comment.
NBC News separately reported the new enforcement policy and obtained an administration response. HHS spokesperson Emily Hilliard said the department, under President Donald Trump’s leadership, was putting prevention and patient safety at the center of health care and trying to address risks from black-market peptides. Critics quoted by NBC argued that the action could expose patients to compounds that have not been adequately tested.
Why HHS says broader access is needed
Health Secretary Robert F. Kennedy Jr. has argued that legal access through regulated compounding pharmacies would steer consumers away from a gray market in products sold online as being for research only. Kennedy has publicly described himself as a supporter of peptides and has said he used BPC-157 for a muscle injury. Supporters say pharmacy preparation with sourcing and reporting rules is safer than buying unidentified vials from overseas sellers.
FDA scientists have emphasized a different risk. In 2023, the agency placed several peptides, including BPC-157 and TB-500, in a category of substances that may present significant safety concerns when compounded, citing potential problems such as immune reactions, kidney injury and tumor-related risks. At a July 2026 advisory meeting, FDA staff said the substances under review still lacked sufficient evidence of safety and effectiveness.
What happens next
An FDA advisory committee narrowly recommended in July that six of seven peptides under consideration be added to the compounding list. That recommendation was nonbinding. A permanent change still requires the FDA to propose a rule, accept public comment and issue a final rule. Until that process is completed or the temporary policy changes, access rests on enforcement discretion rather than an approval finding.
Sources and image credit
- Associated Press — FDA scientists opposed the administration’s move to ease peptide access
- PBS NewsHour — accessible republication of the Associated Press report
- NBC News — HHS enforcement policy, administration response and independent reporting
- FDA — July 23–24 Pharmacy Compounding Advisory Committee meeting record
- Image: U.S. Food and Drug Administration photo on Wikimedia Commons
- Original full-resolution FDA image